Skip to main content
BIIB
NASDAQ Life Sciences

Biogen's Litifilimab Shows Significant Efficacy in Second Positive Phase 2 Lupus Trial, Bolstering Breakthrough Status

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$183.84
Mkt Cap
$26.98B
52W Low
$110.035
52W High
$202.41
52W Position info
67% above low
Off High info
9.2% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

BIIB sits 67% above its 52-week low of $110.035.

Summary

Biogen announced positive results from the Phase 2 AMETHYST study for litifilimab in cutaneous lupus erythematosus (CLE), demonstrating a statistically significant 11.8% higher reduction in disease activity compared to placebo. This marks the second positive Phase 2 trial for litifilimab, consistent with the earlier LILAC study, and reinforces the drug's recently granted FDA Breakthrough Therapy Designation. The positive data de-risks a key pipeline asset for Biogen, as litifilimab targets a disease with significant unmet needs and no currently approved targeted therapies. Traders will be watching for the progression of the ongoing Phase 3 study, as successful development could open a new market for the company.

At the time of this announcement, BIIB was trading at $183.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27B. The 52-week trading range was $110.04 to $202.41. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

BIIB - Latest Insights

BIIB
Nov 09, 2026, 1:02 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $248.35
Real-time Price: $258.11 info
Change: +$9.76 (+4%) info
Market Cap: $38.154B info
BIIB
Oct 28, 2026, 6:23 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $252.73
Real-time Price: $258.11 info
Change: +$5.38 (+2%) info
Market Cap: $38.154B info
BIIB
Oct 28, 2026, 6:07 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $252.73
Real-time Price: $258.11 info
Change: +$5.38 (+2%) info
Market Cap: $38.154B info
BIIB
Oct 28, 2026, 6:00 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $252.73
Real-time Price: $258.11 info
Change: +$5.38 (+2%) info
Market Cap: $38.154B info
BIIB
Oct 02, 2026, 11:20 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $221.12
Real-time Price: $258.11 info
Change: +$36.99 (+17%) info
Market Cap: $38.154B info